MIRM Earnings & Financial Statements
Mirum Pharmaceuticals, Inc.
$79.96
+$0.34(+0.43%)
52
Overall
40
Value
45
Tech
71
Quality
Market Cap
$5.19B
Volume
975.11K
52W Range
$63.23 - $130.00
Target Price
$144.20
MIRM earnings and financial statements: Mirum Pharmaceuticals, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
MIRM Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $521.31M | $336.89M | $186.37M | $77.06M | $19.14M |
| Cost of revenue | $100.24M | $81.64M | $47.04M | $12.37M | $1.90M |
| Operating income | -$22.14M | -$87.61M | -$109.15M | -$131.22M | -$173.41M |
| EBITDA | $18.95M | -$47.31M | -$135.37M | -$122.85M | -$169.72M |
| Net income | -$23.36M | -$87.94M | -$163.41M | -$135.66M | -$83.99M |
| EPS (diluted) | $-0.47 | $-1.85 | $-4.00 | $-4.02 | $-2.77 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $842.81M | $670.75M | $646.62M | $352.91M | $294.65M |
| Total liabilities | $528.12M | $445.11M | $397.95M | $210.87M | $174.44M |
| Shareholders’ equity | $314.69M | $225.64M | $248.67M | $142.04M | $120.21M |
| Cash and equivalents | $296.68M | $222.50M | $286.33M | $28.00M | $31.34M |
| Long-term debt | $317.31M | $316.05M | $307.04M | $1.26M | $1.90M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | $55.83M | $10.32M | -$70.94M | -$120.14M | -$132.76M |
| Capital expenditure | -$954.0K | -$20.99M | -$20.11M | -$278.0K | -$19.02M |
| Free cash flow | $54.87M | -$10.67M | -$91.05M | -$120.41M | -$132.78M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | MIRM | $79.96 | +0.4% | 975.11K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Mirum Pharmaceuticals, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW